643 related articles for article (PubMed ID: 9314631)
1. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
[TBL] [Abstract][Full Text] [Related]
2. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
3. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
Ahmed AB; Home PD
Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
[TBL] [Abstract][Full Text] [Related]
4. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
5. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
Roach P; Malone JK
Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
[TBL] [Abstract][Full Text] [Related]
6. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed AB; Mallias J; Home PD
Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
[TBL] [Abstract][Full Text] [Related]
7. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
8. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
[TBL] [Abstract][Full Text] [Related]
9. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
Ahmed AB; Home PD
Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
[TBL] [Abstract][Full Text] [Related]
10. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
Anderson JH; Brunelle RL; Keohane P; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
Arch Intern Med; 1997 Jun; 157(11):1249-55. PubMed ID: 9183237
[TBL] [Abstract][Full Text] [Related]
11. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.
Malone JK; Woodworth JR; Arora V; Yang H; Campaigne BN; Hallé JP; Yale JF; Grossman LD
Clin Ther; 2000 Feb; 22(2):222-30. PubMed ID: 10743981
[TBL] [Abstract][Full Text] [Related]
12. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
13. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
14. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
[TBL] [Abstract][Full Text] [Related]
15. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
Ross SA; Zinman B; Campos RV; Strack T;
Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
[TBL] [Abstract][Full Text] [Related]
18. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.
Bastyr EJ; Stuart CA; Brodows RG; Schwartz S; Graf CJ; Zagar A; Robertson KE
Diabetes Care; 2000 Sep; 23(9):1236-41. PubMed ID: 10977012
[TBL] [Abstract][Full Text] [Related]
19. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
Hermanns N; Burkert A; Haak T
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
[TBL] [Abstract][Full Text] [Related]
20. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes.
Deeb LC; Holcombe JH; Brunelle R; Zalani S; Brink S; Jenner M; Kitson H; Perlman K; Spencer M
Pediatrics; 2001 Nov; 108(5):1175-9. PubMed ID: 11694699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
